Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $1.470
America/New_York / 31 des 1970 @ 19:00
RATING 2022-08-12 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.704 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.12x |
Company: PE -0.704 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.421 - 1.519 ( +/- 3.33%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-08-12 | Giordano Michael F | Sell | 8 994 | Common Stock, par value $0.0001 |
2022-08-12 | Goldfischer Carl | Sell | 13 060 | Common Stock, par value $0.0001 |
2022-08-12 | Goldfischer Carl | Sell | 8 994 | Common Stock, par value $0.0001 |
2022-08-12 | Goldfischer Carl | Sell | 3 380 951 | Common Stock, par value $0.0001 |
2022-08-12 | Conroy Kevin T | Sell | 53 324 | Common Stock, par value $0.0001 |
INSIDER POWER |
---|
-88.97 |
Last 98 transactions |
Buy: 31 679 726 | Sell: 42 571 145 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.470 (0.00% ) |
Volume | 0 mill |
Avg. Vol. | 4.18 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..